Member Info for ZzTop1

a) https://mobile.twitter.com/falcon_study

b) Basing this on Ophidian's contribution: https://mobile.twitter.com/Ophidian18/status/1305995626866507781

My take and at the risk of coming across as a deramper is Condor or at least the Falcon Study only recruited its first patients 4 days ago. I'm not expecting Bams news for a few weeks yet.

LFD, no pilot batch for clinical validation until the tech transfer's complete.

Moonshot timelines looking like Feb 2021, the boats still being built and we're going as fast as our partners can take us.

My dog hates peanut butter. Loves to chase after balls though.

Thought I'd add something useful to the board today, see if I can 5 likes.

BTW, it's not affirmers

Condor Falcon Study has officially kicked off. If the govt want to save Xmas, this study needs to move fast:

https://mobile.twitter.com/falcon_study

What I find confusing is where Bams is being clinically validated. Falcon, Raptor or other?

1. Choose popular PI stock (easily parted with money), research, express doubts on LSE bb
2. Increase negativity on bb when signals suggest downwards pressure
2.1. Or go quiet when price increases
3. Wait for technical signals to suggest short and ramp up negativity on bb through negatively titled message. Await many muppets to respond and keep negativity at top of bb to scare off new investors
4. Pass Go, collect £200 and start again

Please don't feed the animals!

He's been waiting for the candlesticks to signal short :D

Here you go Gazza, remember writing this? :

Patience05 Aug 2020 09:42
Be Patient ....tests - especially a saliva 10 min test - are gold dust!
When they are ready they will deliver - stock up and wait - bumps along the way are guaranteed. Those who dont like waiting should jump - others who are patient will benefit .

Tickled, why are you even a shareholder? Or are you just totally full of bullkaka. Wait, let me guess.

Only 2 weeks ago we had the RNS to say that manufacturing capacity is the key challenge to widespread rollout for the rapid test. Nothing's changed.

The jokes not funny anymore Always. Get a new one.

Please ignore AlwaysShorting until this comedian returns with fresh material.

I call a new bottom for the today.

Only idiots need tick this up.

Or guess the Xmas share price list just to change it up a little?

This must include Bams news too

Crazy board today. Keyboard warriors need to chillax a bit.

Anyways, decent read:

https://www.google.co.uk/amp/s/amp.theguardian.com/world/2020/sep/09/what-is-no-10s-moonshot-covid-testing-plan-and-is-it-feasible

I fly fighter planes. Just thought I'd put it out there.

The SP really should be flying right now!

Probably lots selling to buy back cheaper. All technicals pointing towards a quick short and buy back later. It's why AlwaysShorting back spreading his crap

Always, when did Astrazeneca become a partner?

Or you talking crap again?

I suspect most are excited. I have a £1.66 average and yes I am excited. And without sounding like I am deramping, I'd like to think I've been around long enough to 'believe it when I see it'. Talk of 300% + potential is fine and all but I am one of the excited people who'd like to see £2.50 first.

Bobd29 from what the 9th June Bams RNS says, it would seem CE/FDA will happen following validation so can assume its the same for LFT:

The next step in the development of the final product to run on the installed base of mass spectrometers in clinical laboratories around the world is to evaluate and optimise the BAMS assay using patient samples at laboratory sites in the UK and US which will be done imminently before moving to manufacturing, clinical validation to quantify the sensitivity and specificity and CE/FDA approval for professional use in the summer.

We also know from the most recent RNS that the expected demand for the LFT will be UK and elsewhere as the search for global partners continues. I agree, would be nice to learn more about global approvals although news of a new non UK manufacturing partner would make a great RNS :

Manufacturing capacity is therefore the key challenge that has to be met in achieving widespread roll-out of Avacta's saliva-based rapid antigen test. We therefore continue to actively seek additional manufacturing partners globally to be able to provide the volume of tests that will be required in the UK and elsewhere.

Check out the Condor Assay Validation Development Pathways slide:

https://www.google.com/url?sa=t&source=web&rct=j&url=https://www.bioindustry.org/uploads/assets/uploaded/aef52e62-e762-4f1e-ad2efc0d49f85583.pdf&ved=2ahUKEwih45el3tLrAhVIqaQKHfc8A8gQFjAAegQIARAB&usg=AOvVaw1lENrD3hK6dm0mS4X8RURE&cshid=1599333955283

Bams should be towards the end of this process by now and LFT will hopefully go through quickly once the pilot batch is ready. The fact there is no news on Bams as yet is only good news as we would have heard otherwise by now.

Based on the RNS's Bams is being evaluated and validated through Condor whereas LFT only being validated through Condor. Evaluation should already be completed by LSTM using the prototype. I suspect LFT will also be viewed as a promising candidate.

Pillar 3, 4 and 5 slides would be useful. No luck finding them although know the 3 & 4 conference ran July 10th.